Samuel Sperry

473 total citations
6 papers, 86 citations indexed

About

Samuel Sperry is a scholar working on Molecular Biology, Organic Chemistry and Genetics. According to data from OpenAlex, Samuel Sperry has authored 6 papers receiving a total of 86 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 1 paper in Organic Chemistry and 1 paper in Genetics. Recurrent topics in Samuel Sperry's work include RNA modifications and cancer (3 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Carbohydrate Chemistry and Synthesis (1 paper). Samuel Sperry is often cited by papers focused on RNA modifications and cancer (3 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Carbohydrate Chemistry and Synthesis (1 paper). Samuel Sperry collaborates with scholars based in United States. Samuel Sperry's co-authors include Harmon Zuccola, Weichao Chen, William J. Kargo, Azin Nezami, Beth A. Fleck, Phillip W. Snyder, Lance Goulet, Dean Stamos, Michael C. Liu and Khisal A. Alvi and has published in prestigious journals such as Blood, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Samuel Sperry

6 papers receiving 85 citations

Peers

Samuel Sperry

MB

CTM

IMMUN

ONCOL

MC

Sarah Sarker United Kingdom

Carla Mottini Italy

Evangelia Vartholomaiou Switzerland

Andrea Zauli Italy

Jordan Lane United Kingdom

Nadine Reischmann Germany

Steve Schneider United States

Lee Walmsley United Kingdom

Marta Wylot United Kingdom

Xinyue Zhang China

Sarah Sarker United Kingdom

Samuel Sperry

90 ×1.2

MB

17 ×0.8

CTM

17 ×1.2

IMMUN

15 ×1.4

ONCOL

6 ×0.6

MC

Citations per year, relative to Samuel Sperry Samuel Sperry (= 1×) peers Sarah Sarker

Countries citing papers authored by Samuel Sperry

Since Specialization

Citations

This map shows the geographic impact of Samuel Sperry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Sperry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Sperry more than expected).

Fields of papers citing papers by Samuel Sperry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Sperry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Sperry. The network helps show where Samuel Sperry may publish in the future.

Co-authorship network of co-authors of Samuel Sperry

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Sperry. A scholar is included among the top collaborators of Samuel Sperry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Sperry. Samuel Sperry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Nilewski, Christian, Garrick K. Packard, Alan X. Xiang, et al.. (2021). 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties. Bioorganic & Medicinal Chemistry Letters. 47. 128111–128111. 2 indexed citations

2.

Thompson, Peggy A., Nathan P. Young, Craig R. Stumpf, et al.. (2019). Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers. Molecular Cancer Therapeutics. 18(12_Supplement). B133–B133. 3 indexed citations

3.

Webster, Kevin R., Vikas Goel, Jocelyn Staunton, et al.. (2017). Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade. Cancer Research. 77(6_Supplement). PR11–PR11. 3 indexed citations

4.

Webster, Kevin R., Vikas Goel, Jocelyn Staunton, et al.. (2017). Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity. Cancer Research. 77(13_Supplement). 596–596. 3 indexed citations

5.

Webster, Kevin R., Vikas Goel, Gregory S. Parker, et al.. (2015). eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 126(23). 1554–1554. 20 indexed citations

6.

Ernst, Justin T., Michael C. Liu, Samuel Sperry, et al.. (2014). Identification of Novel HSP90α/β Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington’s Disease. Journal of Medicinal Chemistry. 57(8). 3382–3400. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact